Infectious Disease · Medical Literature
Virologic insights from the phase 3 REDPINE trial: remdesivir in renally impaired and immunocompromised patients with COVID-19.
Abstract
Remdesivir inhibits the SARS-CoV-2 RNA-dependent polymerase (Nsp12). Here, we present virology analyses from the Phase 3 REDPINE trial in participants with impaired kidney function hospitalized for COVID-19 and treated with remdesivir or placebo for 5 days. Out of 243 participants enrolled and treated in the study, 42 participants had solid organ transplantation (SOT) and received immunosuppressive medication prior to and during the study. Nasopharyngeal swabs were collected at baseline and through Day 29. Virology assessments were performed using SARS-CoV-2 RT-qPCR, next-generation sequencing, and site-directed mutagenesis in a SARS-CoV-2 replicon system. Remdesivir treatment demonstrated significantly greater reductions from baseline in viral load on Day 5 and Day 7 compared with placebo (P ≤ 0.034). In the remdesivir treatment group, participants with SOT showed significantly smaller viral load reductions from baseline on Days 5, 7, and 14 compared with participants without SOT (all P 13-day faster time to viral load decline by extending the remdesivir treatment duration from 5 days to 10 days. In four participants treated with remdesivir, emergent substitutions in Nsp12 (E136V, M794I, and C799F) with low-level reduced in vitro susceptibility to remdesivir (≤3.4 fold change in half-maximal effective concentration) were observed 9 days after cessation of remdesivir treatment. Three of the four participants had undergone SOT. Overall, remdesivir demonstrated antiviral activity in participants with impaired kidney function, with delayed viral clearance in SOT recipients and rare posttreatment emergence of Nsp12 substitutions that confer low-level reduced susceptibility to remdesivir.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT04745351; EudraCT registration no. 2020-005416-22.
Clinical relevance
In hospitalized patients with impaired kidney function receiving 5-day remdesivir therapy for COVID-19, does remdesivir produce meaningful SARS-CoV-2 viral load reductions, and how do virologic outcomes differ in the immunocompromised solid organ transplant (SOT) subgroup—including the emergence of resistance mutations and potential benefit from extended treatment duration? __SNAPSHOT__ {"studyDesign":"Virologic substudy of a Phase 3 randomized, double-blind, placebo-controlled, parallel-group trial (REDPINE; NCT04745351)","setting":"International, multicenter; 55 centers across 5 countries (Brazil, Portugal, Spain, United Kingdom, and United States); enrollment March 2021 – March 2022","sampleSize":"n=243 enrolled and treated (remdesivir: n=163; placebo: n=80); 42 participants had prior solid organ transplantation (SOT). For resistance analyses, sequencing data from 60 participants (remdesivir: n=41; placebo: n=19).","population":"Participants aged ≥12 years hospitalized for COVID-19 pneumonia with acute kidney injury (37.0%), chronic kidney disease (26.3%), or kidney failure including dialysis (36.6%); 12.8% were vaccinated against COVID-19; 17.3% were SOT recipients on immunosuppressive therapy. Enrollment concluded early; study was underpowered for its primary clinical efficacy endpoint.","intervention":"Intravenous remdesivir 200 mg on Day 1, then 100 mg once daily through Day 5 (5-day course); no dose adjustment for renal impairment","comparator":"Intravenous placebo for 5 days","primaryOutcome":"For this virologic analysis: change from baseline in SARS-CoV-2 nasopharyngeal viral load (log10 copies/mL) assessed by RT-qPCR at Days 3, 5, 7, 14, 21, and 29. Secondary assessments included emergence of Nsp12 resistance-associated substitutions by next-generation sequencing, phenotypic susceptibility testing via SARS-CoV-2 replicon system, and mathematical modeling of viral load kinetics in kidney transplant recipients. The parent trial's primary efficacy endpoint was composite all-cause mortality or invasive mechanical ventilation (IMV) through Day 29.","followUp":"Nasopharyngeal swabs through Day 29; safety follow-up through Day 60","fundingSource":"Industry (Gilead Sciences); multiple investigators disclosed financial relationships with Gilead Sciences"}
Key findings
Primary virologic outcome: Remdesivir produced statistically significantly greater reductions from baseline in SARS-CoV-2 nasopharyngeal viral load compared with placebo at both Day 5 and Day 7 (all P ≤ 0.034). At Day 5, the least-squares mean (SE) change from baseline was −1.12 (0.16) log10 copies/mL in the remdesivir group versus −0.64 (0.21) log10 copies/mL in the placebo group, yielding a between-group difference of −0.48 log10 copies/mL (95% CI, −0.93 to −0.04; P = 0.033). Day 7 results and confidence intervals beyond Day 5 were not fully reported in the available abstract. NNT for the virologic endpoint was not reported and cannot be calculated from available data. SOT subgroup: Among remdesivir-treated participants, those with SOT demonstrated statistically significantly smaller viral load reductions from baseline compared with non-SOT participants at Days 5, 7, and 14 (all P 13-day faster time to viral load decline if remdesivir treatment duration were extended beyond 5 days; this is a modeling estimate, not a clinical outcomes result. Resistance analyses (from the companion conference report): Among 60 participants with sequencing data, emergent Nsp12 amino acid substitutions were observed in 8/41 (19.5%) in the remdesivir group versus 1/19 (5.3%) in the placebo group. In 4 remdesivir-treated participants, Nsp12 substitutions with low-level reduced susceptibility (2.9- to 3.4-fold change in EC50) were identified (M794I [n=2], C799F [n=1], E136V [n=1]) in samples collected approximately 9 days after treatment cessation; 3 of these 4 participants were SOT recipients on immunosuppressive therapy. The clinical significance of these substitutions in terms of patient outcomes was not established. NNH for resistance emergence was not calculable from available data.
Practice implications
This virologic analysis establishes that a standard 5-day remdesivir course produces statistically significant and measurable SARS-CoV-2 nasopharyngeal viral load reductions in hospitalized patients with severe kidney impairment compared with placebo, supporting the FDA label expansion for this population. However, the study was explicitly underpowered for its primary clinical efficacy endpoint (mortality or IMV), meaning it does not establish that remdesivir reduces death or need for mechanical ventilation in this kidney-impaired population. The virologic benefit in non-transplant renally impaired patients appears consistent with findings from the general-population ACTT-1 and prior pivotal trials. The SOT subgroup finding—significantly blunted viral load reduction at Days 5, 7, and 14—is clinically important and hypothesis-generating: it suggests that the standard 5-day course may be virologically insufficient for immunocompromised transplant recipients. The mathematical modeling result (>13-day faster viral decline with extended therapy) is a pharmacokinetic/dynamic simulation only and has not been tested in a clinical trial; it should not be used to justify extended treatment outside of a research setting or compassionate use protocol. The emergence of low-level remdesivir resistance-associated Nsp12 substitutions in 3 of 4 affected participants who were also SOT recipients is a clinically concerning signal, consistent with prior case series, and underscores the risk of resistance emergence during prolonged or suboptimal viral suppression in immunocompromised hosts. Results apply most directly to hospitalized adults with AKI, CKD stage 4–5, or kidney failure, including dialysis patients. Pediatric patients (≥12 years), patients with non-kidney immunocompromising conditions (e.g., hematologic malignancy, HIV), outpatients, and those with eGFR 30–60 mL/min/1.73 m² were not the target population. Importantly, only the abstract was available for this virologic analysis (published August 4, 2026); full methods, all time-point data, modeling assumptions, and resistance analysis integration await complete manuscript review. __LIMITATIONS__ Trial was explicitly underpowered for the primary clinical endpoint (mortality or IMV); enrollment concluded early at 243 of a planned larger sample, precluding definitive clinical efficacy conclusions.,This is a virologic/mechanistic secondary analysis of a trial not designed or powered for virologic endpoints as primary outcomes; multiplicity of comparisons is a concern.,SOT subgroup is small (n=42 total; subset with sequencing data even smaller), limiting precision and generalizability of SOT-specific findings.,Mathematical modeling of extended treatment benefit is hypothesis-generating only; no clinical trial data support extended remdesivir duration in kidney transplant recipients.,Resistance analysis sequencing data available for only 60 of 243 participants (24.7%), introducing selection bias (enriched for virologic failures and severe outcomes).,Low-level phenotypic resistance (2.9–3.4-fold EC50 change) detected post-treatment; clinical relevance (treatment failure, transmission) was not established.,Nasopharyngeal viral load is a surrogate endpoint; correlation with lower respiratory tract viral burden, clinical outcomes, or transmissibility is not established.,Enrollment occurred during Delta and Omicron waves (March 2021–March 2022); generalizability to current circulating SARS-CoV-2 variants is uncertain.,Industry sponsorship (Gilead Sciences) with multiple investigator financial ties introduces risk of reporting bias.,Only the abstract was available at time of summary; full data tables, forest plots, and subgroup analyses have not been reviewed. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ In hospitalized patients with severe kidney impairment, 5-day intravenous remdesivir produces statistically significant but modest SARS-CoV-2 viral load reductions compared with placebo, supporting its use without dose adjustment in this population. SOT recipients on immunosuppression show significantly attenuated virologic responses, and low-level remdesivir resistance-associated Nsp12 mutations emerged predominantly in this subgroup—a clinically concerning signal warranting resistance surveillance. Extended treatment duration in kidney transplant recipients is supported only by mathematical modeling and must be validated in prospective trials before practice adoption.